NOVARTIS

Clinical Trial Results Summary

A clinical trial to learn more about the safety of HDM201 and how the body processes it in people with and without liver disease

Thank you!

Thank you to the participants who took part in the clinical trial. Every participant helped the researchers learn more about the trial drug **HDM201**, also called siremadlin.

Novartis sponsored this trial and believes it is important to share what was learned from the results of this trial with the participants and the public. We hope this helps the participants understand their important role in medical research.

Trial information

Trial number: CHDM201X2105

Novartis drug studied: HDM201, also called siremadlin

Sponsor: Novartis

If you were a participant and have any questions about the results, please talk to the doctor or staff at the trial site.

This summary only shows the results of a single clinical trial. Other clinical trials may have different results.

What was the main purpose of this trial?

The purpose of this trial was to help researchers learn if liver disease changes how the body processes the trial drug HDM201. The researchers also wanted to learn about the safety of HDM201 in people with and without liver disease.

Liver disease is a group of conditions that cause liver damage and scarring. Because the liver helps to process certain drugs, liver disease can change how the body processes drugs like HDM201.

HDM201 is a trial drug designed to treat certain types of cancer. This trial did not look at the effects of HDM201 on cancer.

Why the researchers did this trial:

Many health authorities require a trial like this before they can approve certain types of drugs. Results from this type of trial can also inform how doctors may prescribe the drug for people with liver disease.

The trial's purpose was to answer these main questions:

- Did liver disease change how the body processes HDM201?
- What medical problems, also called adverse events, happened during this trial?
  - ↳ An **adverse event** is any sign or symptom that participants have during a trial.

How long was this trial?

The trial began in December 2022 and ended in September 2023. The participants began this trial on different dates.

Who was in this trial?

38 participants received treatment in this trial – 25 men and 13 women. Participants' ages ranged from 25 to 70 years. Their average age was 57 years. The number of participants by race is shown below.

Race

1	American Indian or Alaska Native
2	Black or African American
34	White
1	Other

Out of the 38 participants:

- 15 participants were **healthy** and did not have liver disease
- 8 participants had **mild liver disease**
- 8 participants had **moderate liver disease**
- 7 participants had **severe liver disease**

Researchers included healthy participants so they could compare the trial results to those that had liver disease.

The trial took place in the United States.

What treatment did the participants receive?

The treatment in this trial was:

HDM201, which participants took as one 10 milligram (mg) capsule by mouth.

The participants, researchers, and trial staff knew what treatment the participants took. Participants could continue taking prescribed medicine for liver disease during this trial.

What happened during this trial?

Before treatment — About 1 month

Trial staff checked the participants to make sure they could be in this trial.

During treatment — About 1 week

Every participant took HDM201 one time.

Participants stayed at the trial site for 8 days. Trial staff took blood samples to measure the amount of HDM201 in the participants' blood many times during their trial stay.

The graphic below shows how many participants were in each group.



After treatment — About 1 month

Trial staff contacted participants one time after they left the site to check on their health and any medical problems.

What were the main results of this trial?

Did liver disease change how the body processes HDM201?

The researchers concluded that moderate and severe liver disease changed how the body processes HDM201. Mild liver disease did not change how the body processes HDM201.

To find this out, the trial staff took many blood samples from each participant after they received HDM201. The researchers measured the participants' blood samples for the:

- Time it took HDM201 to reach peak level
- Peak level of HDM201 in the blood
- Total amount of HDM201 in the blood
- Length of time HDM201 stayed in the blood

Then, the researchers compared these measures for **participants with liver disease** to **healthy participants**. Below is a summary of what the researchers found.

The time it took HDM201 to **reach the peak level** was:

About the same for participants with mild, moderate, or severe liver disease

The **peak level** of HDM201 was:

About the same in participants with mild, moderate, or severe liver disease

The **total amount** of HDM201 was:

About the same in participants with mild liver disease

Higher in participants with moderate or severe liver disease

The length of time HDM201 **stayed in the blood** was:

About the same for participants with mild liver disease

Longer for participants with moderate or severe liver disease

What medical problems, also called adverse events, happened during this trial?

Trial doctors keep track of all **adverse events** that happen in trials, even if they think the adverse events are not related to the trial treatments.

Many trials are needed to know if a drug or treatment causes an adverse event.

This section is a summary of the adverse events that happened from the day participants received trial treatment until about 1 month after treatment.

An **adverse event** is:

- Any **sign or symptom** that the participants have during a trial
- Considered **serious** when it is life-threatening, causes lasting problems, the participant needs hospital care, or results in death

Adverse events **may** or **may not** be caused by treatments in the trial.

Some of the participants (2 of 38 participants) had adverse events. None of the participants had adverse events that were considered serious. None of the participants left the trial due to an adverse event. The researchers concluded there were no new safety concerns for HDM201 in this trial.

How many participants had adverse events?

	Healthy participants 15 participants	**Participants with mild liver disease** 8 participants	**Participants with moderate liver disease** 8 participants	**Participants with severe liver disease** 7 participants
Had at least 1 **serious adverse event**	**0 of 15** 0%	**0 of 8** 0%	**0 of 8** 0%	**0 of 7** 0%
Had at least 1 **other adverse event**	**1 of 15** 7%	**0 of 8** 0%	**0 of 8** 0%	**1 of 7** 14%
Left the trial due to an adverse event	**0 of 15** 0%	**0 of 8** 0%	**0 of 8** 0%	**0 of 7** 0%
Died during the trial	**0 of 15** 0%	**0 of 8** 0%	**0 of 8** 0%	**0 of 7** 0%

What serious adverse events did the participants have?

No participants had serious adverse events. No participants died.

What other adverse events did the participants have?

2 participants had other adverse events.

The table below shows the other adverse events that happened.

	Healthy participants 15 participants	Participants with mild liver disease 8 participants	Participants with moderate liver disease 8 participants	Participants with severe liver disease 7 participants
Headache	1 of 15 7%	0 of 8 0%	0 of 8 0%	0 of 7 0%
Rash	0 of 15 0%	0 of 8 0%	0 of 8 0%	1 of 7 14%

What was learned from this trial?

Researchers learned about how the body processes HDM201 and its safety in participants with and without liver disease.

The researchers concluded that when compared to healthy participants:

- Moderate and severe liver disease changed how the body processes HDM201
- Mild liver disease did not change how the body processes HDM201

The researchers also concluded that there were no new safety concerns for HDM201.

When this summary was written, the sponsor had no plans for future trials with HDM201.

Where can I learn more about this trial?

More information about the results and adverse events in this trial can be found in the scientific summary of the results available on the Novartis Clinical Trial Results website **www.novctrd.com**

Follow these steps to find the scientific summary:



For more information about this trial, go to any of these websites:

- **clinicaltrials.gov** – search using the number **NCT05599932**

Full clinical trial title: A Phase 1, open-label, multi-center, single-dose, parallel-group study to evaluate the pharmacokinetics of siremadlin (HDM201) in participants with mild, moderate and severe hepatic impairment compared to matched healthy control participants

NOVARTIS

Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.

1-888-669-6682 (US) | +41-61-324 1111 (EU)

www.novartis.com/clinicaltrials